Approval · Notice of Compliance 5319 · 2004
MAXIPIME: Notice of Compliance 5319
Issued September 10, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5319
- Date
- September 10, 2004
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To provide for a revision of the dosage recommendations for patients with renal impairment in the dosage and administration section of the product monograph
- Therapeutic class
- Antibiotic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MAXIPIME | Not yet assigned | — |
Medicinal ingredients
- CEFEPIME HCL 0.5 G per VIAL
- CEFEPIME HCL 1 G per VIAL
- CEFEPIME HCL 2 G per VIAL